Letters to the Editor
Miglitol and Hepatotoxicity in Type 2 Diabetes Mellitus
Am Fam Physician. 2000 Jul 15;62(2):315-318.
to the editor: Drs. Florence and Yeager1 provided a current and comprehensive summary of the screening, diagnosis and treatment of patients with type 2 diabetes (formerly non–insulin-dependent diabetes). However, I want to point out that their discussion about the alpha-glucosidase inhibitors, miglitol (Glyset) and acarbose (Precose) tablets, is inaccurate with respect to hepatotoxicity.
The authors make the following statements: “Dose-dependent hepatotoxicity is associated with this drug class, so liver function tests should be carefully monitored in patients receiving higher dosages of these medications (i.e., more than 50 mg three times daily). Transaminase elevations are reversible with discontinuation of the drug and are often asymptomatic. Serum transaminase levels should be checked every three months for the first year patients take the medication and periodically thereafter.”1 These statements are misleading with respect to miglitol because one of the pivotal U.S. clinical trials revealed a similar and very low incidence of elevated liver enzymes when the drug was compared with placebo.2
As a result of these and other clinical trial safety data on miglitol, the U.S. package insert for miglitol does not contain a precaution statement about hepatotoxicity; monitoring of transaminase levels is unnecessary, and the drug is not contraindicated in patients with cirrhosis.3
In contrast, the U.S. package insert for acarbose includes the following statement in the precautions section: “In long-term studies (up to 12 months, and including Precose doses up to 300 mg t.i.d.) conducted in the United States, treatment-emergent elevations of serum transaminases (AST and/or ALT) above the upper limit of normal (ULN), greater than 1.8 times the ULN and greater than 3 times the ULN occurred in 14 percent, 6 percent and 3 percent, respectively, of Precose-treated patients as compared to 7 percent, 2 percent, and 1 percent of placebo-treated patients.”4 According to the product label, acarbose is contraindicated in patients with cirrhosis.
A synopsis of clinical trial safety data for acarbose concluded that sustained treatment-emergent increases in serum transaminase levels of at least 1.8 times the ULN were evident in 3.8 percent of patients receiving acarbose versus 0.9 percent on placebo in U.S. clinical trials.5 A recent, thorough review of clinical trial safety data for miglitol confirmed that “Unlike acarbose, treatment with miglitol was not associated with elevated serum transaminase (alanine or aspartate transferase) levels.”6 In conclusion, I want to emphasize that physicians should be aware that the alphaglucosidase inhibitor, miglitol, has not been linked to hepatotoxicity.
Dr. Carlson is an employee of Pharmacia & Upjohn.
1. Florence JA, Yeager BF. Treatment of type 2 diabetes mellitus. Am Fam Physician. 1999;59:2835–44.
2. Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX, Krol A. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care. 1994;17:20–9.
3. Glyset [Package insert]. West Haven, Conn.: Bayer, 1999.
4. Physicians' desk reference. 53rd ed. Montvale, N.J.: Medical Economics 1999:667–9.
5. Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs. 1993;46:1025–54.
6. Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000;59:512–49.
editor's note: This letter was sent to the authors of “Treatment of Type 2 Diabetes Mellitus,” who declined to reply.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions